CV Part II Flashcards
(47 cards)
Cholesterol Reducing Agents-HMG-CoA Reductase Inhibitors“Statins”
MOA: decrease the rate of cholesterol production by inhibiting HMG-CoA reductase. The liver requires HMG-CoA reductase to produce cholesterol
Used to:
Reduce total cholesterol
Reduce LDL & VLDL
Increase HDL
Statins- AE’s/warnings
Adverse Effects:
Myopathy: report muscle pain or tenderness, check CPK levels may increase
Rhabdomyolysis (rare)
Hepatotoxicity: check liver function tests may increase
Warnings:
Category X for pregnancy
No statins for pregnant women, alcoholic or viral hepatitis
Statins-most effective when taken at bedtime
Cholesterol Reducing Agents–Bile Acid Sequestrants
MOA: form insoluble complexes with the bile acids in the GI tract, which causes bile acids to be excreted, thereby lowering the cholesterol level
Uses: when dietary management does not lower cholesterol & the LDL cholesterol is high. Can be used with statins.
Common drugs:
- cholestyramine (Questran)
- colesevelam (Welchol)
- colestipol (Colestid)
Bile Acid Sequestrants- AE’s/Nursing implications
Adverse Effects:
- Constipation
- Heartburn, nausea, belching, bloating
Nursing Implications:
- Assess for GI distress, bowel habits
- Can bind with other drugs (advise to take other meds 1 hour before or 4 hours after)
- Powder forms must be taken with a liquid, mixed thoroughly, and never taken dry
Cholesterol Reducing Agents-Fibric Acid DerivativesFibrates
MOA: activate lipase, which breaks down cholesterol
- Suppresses the release of free fatty acids from adipose tissue
- Inhibit the synthesis of triglycerides in the liver
- increase secretion of cholesterol in the bile
Uses:
- Decrease triglyceride levels
- May raise HDLs (by as much as 25%) and lower LDLs
Common drugs:
- gemfibrozil (Lopid)
- fenofibrate (Tricor)
Cholesterol Reducing Agents-Fibric Acid DerivativesFibrates
Adverse effects:
- GI: nausea, diarrhea, abdominal discomfort
- Increased risk of gallstones
- Enhances action of oral anticoagulants – bleeding tendencies
- Enhances effects of statins – myopathy, rhabdomyolysis
Warnings:
- Contraindicated for patients with liver/kidney disease or gallbladder disease
Cholesterol Reducing Agents-Niacin (Nicotinic Acid)
- Vitamin B3
- Lipid-lowering properties require much higher doses than when used as a vitamin
- Effective, inexpensive, often used in combination with other lipid-lowering drugs
Cholesterol Reducing Agents-Niacin (Nicotinic Acid)
MOA: thought to work in the liver and adipose tissue to inhibit the synthesis of triglycerides and VLDL, which can lower LDL
Uses:
- DOC for patients at risk of pancreatitis and have elevated triglycerides
Lowering LDL & triglycerides
Adverse effects:
- Flushing, itching (minimize flushing w/aspirin or NSAIDs 30 minutes prior, take with meals)
- GI distress, hepatotoxicity (jaundice), hyperglycemia, gout
Cholesterol Reducing Agents-Cholesterol Absorption Inhibitorezetimibe (Zetia)
MOA: Inhibits absorption of cholesterol from the small intestine, results in reduced total cholesterol, LDL, triglycerides levels, also increases HDL levels
Drug: ezetimibe (Zetia)
- Works well when taken with a statin drug
Vasodilators: Nitrates
Actions:
- Decrease oxygen demand
- Decrease preload by dilating veins
- Decrease afterload by dilating systemic arteries
Uses:
- First line treatment for immediate & long term prevention of angina; chronic stable angina
- Chest pain from lack of oxygenated blood supply to the heart
Nitrates- AE’s/Warnings
Adverse effects:
- CNS – headaches (vasodilation of blood vessels in brain), syncope, flushed feeling, dizziness, weakness
- CV – hypotension or orthostatic hypotension; reflex tachycardia
Warnings:
- Avoid ETOH while using
- Careful when taking other medications that can decrease BP
- Contraindicated: phosphodiesterase type 5 inhibitors (sildenafil [Viagra])
- Can cause life-threatening hypotension
Nitrates: Administration
Administration routes: sublingual and spray
- May take up to 3 SL tablets, 5 minutes apart, if no relief after 15 minutes, call 911
- Tablets are in dark colored bottle – have to be away from light, heat, and moisture
- Teach patient to carry with them at all times
- Tablets should be replaced every 3 to 6 months after bottle is opened
- Spray should be applied directly to the oral mucosa (do not inhale)
- Tell patient they will experience a tingling feeling under their tongue
- Sit or lie down before taking to prevent hypotension and syncope
Nitrates: Nursing Implications
Administration routes: patches & ointment (transdermal patch; Nitro-dur; Minitran; Nitro-paste)
- Use a hairless area of the upper arms or body
- Rotate sites
- Remove the old patch for 10-12 hours a day & clean off old ointment
- Use gloves to avoid getting ointment on hands
Nitrates: Nursing Implications
Administration routes: oral (Isosorbide)
- Usually sustained released (tolerance can develop; nitrate-free period recommended)
- Prophylaxis – not used to manage an acute angina attack; only used to prevent future attacks
Do not withdraw drug abruptly; doing so may precipitate acute angina
Geriatric patients are more susceptible of developing postural hypotension
Immediate treatment of an M.I
“MONA” or “MONA B” Morphine - Helps alleviate chest pain - Promotes vasodilation - Results in lowering cardiac oxygen demand
Oxygen
- Increase oxygen delivery to ischemic myocardium
Nitroglycerin (NTG)
- Reduces preload -> reduce oxygen demands
- Inc collateral blood flow in the ischemic region of heart
Aspirin
- Suppresses platelet aggregation
Beta Blocker
- Reduces HR and contractility
Heart failure drugs- Digoxin
Positive Inotrope
Cardiac Glycoside
MOA: Influx of Ca++ in cells
- Increasing myocardial contractility (+ inotropic)
- Increase vagal activity: conduction slowed through AV node and refractory time (– chronotropic, – dromotropic)
“Digitalizing” dose to bring serum levels of drug to a therapeutic level quickly
Uses:
- Chronic a-fib
- 2nd line therapy for HF
Digoxin
Adverse effects:
- Cardiac dysrhythmias (especially w/ hypokalemia)
- Non-cardiac effects:
Anorexia (early sign)
Nausea, vomiting
Visual disturbances – blurred vision, yellow vision, halo’s
Potassium – hypokalemia can lead to digoxin toxicity
- Especially if patient is taking a potassium-depleting diuretic
Digoxin: Nursing Implications
Predispose to toxicity: hypokalemia, renal dysfunction
Very narrow therapeutic index (0.5 to 2 ng/mL)
Check apical pulse for one minute before administering digoxin
- Adult: 60 or below – hold digoxin, report signs of digoxin toxicity
Antidote:
- Digoxin immune Fab (Digibind, Digifab)
Anticoagulants
Prevent formation of new clots & extension of clots already present by inhibiting certain clotting factors
Have no direct effect on formed clots
Used prophylactically to prevent
- Clot formation (thrombus)
- An embolus (dislodged clot)
Risks: bleeding
Dx: coagulation panel: clotting time (measures how long it takes blood to clot)
Anticoagulants: Heparin
Action: Short-term use; acts on thrombin (prolong clotting time). Prevents clot formation, but does not break down clots
Uses:
- Short-term or emergency treatment (MI, DVT) to prevent further thrombus formation/embolization
- Prevention of DVT/PE
Adverse effects:
- Bleeding
- Heparin-induced thrombocytopenia (HIT)*** (an antibody-mediated reaction characterized by a profound decrease in platelets; potentially life-threatening and can cause thrombosis)
- Allergic reactions
Anticoagulants: Heparin
Nursing: Monitor aPTT (activated partial thromboplastin time)
When heparin is used therapeutically (for treatment), measurement of aPTT (usually every 6 hours) is necessary.
- aPTT normally 40 seconds Heparin: 1.5-2.5x normal (~ 80 seconds)
Antidote: protamine sulfate
Prophylaxis: 5,000 units subcutaneously two or three times a day; does not need to be monitored when used for prophylaxis
Anticoagulants: HeparinNursing Implications
Assess for bleeding in urine, stool, venipuncture sites, nose, gums, wounds/incisions
Know proper application for SQ or IV route; rotate sites for SQ & do not rub the injection site; use the abdomen for SQ route
Monitor aPTT which should be 1.5 to 2.5 times the normal range for a therapeutic effect
Monitor CBC esp. platelets
Low Molecular Weight Heparin (LMWH): enoxaparin (Lovenox)
Action: similar to heparin, inhibit clotting factors specific to factor Xa
- Synthetic smaller molecular structure
- More predictable anticoagulant response
Advantage: Do not need to monitor aPTT, SQ injections at home
Drugs:
- enoxaparin (Lovenox)
- dalteparin (Fragmin)
Uses:
- Prevention and management of DVT/PE
- Prevention of ischemic complications (unstable angina to prevent MI)
Adverse effects:
- Bleeding – can use protamine sulfate as antidote
Anticoagulants (oral): warfarin (Coumadin)
Action: inhibit vitamin K–dependent clotting factors II, VII, IX, and X. Prevents clotting by prolonging prothrombin time/INR. Takes approximately 3-5 days for full effect.
Uses:
- Slow down or prevent the extension of a blood clot; will not dissolve existing clot
- Long-term prevention/management of: DVT/PE, embolization associated with atrial fibrillation, prosthetic heart valves
Adverse effects: bleeding (hematuria, epistaxis, ecchymosis, melena, black/tarry stools, bleeding gums)